All In Biotech

Drug Trial Radar · NCT07275736

A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases

An Exploratory Clinical Study on the Safety and Efficacy of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Autoimmune Neurological Diseases

Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Mar 1, 2025

Primary completion

Jun 1, 2027

Study completion Jun 1, 2029

Sponsor

Lead sponsor
Juventas Cell Therapy Ltd.Industry
Sponsor type
Industry
Collaborators
Beijing Tiantan Hospital
First posted
Dec 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of CNCT19 cell injection in the treatment of patients with relapsed/refractory Neurological Autoimmune Diseases.

Conditions

  • Neurological Autoimmune Diseases

Interventions

  • CNCT19 cell injectionBiological

    A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose-limiting toxicities (DLTs)Time frame: Up to 28 days after infusion
  2. Number of participants with adverse events (AEs)/serious adverse events (SAEs)Time frame: up to Month 36

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.